Enterprise Value
1.083B
Cash
317.9M
Avg Qtr Burn
-42.65M
Short % of Float
20.59%
Insider Ownership
19.65%
Institutional Own.
84.99%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OJEMDA™ (Tovorafenib) (DAY101) (pan-RAF inhib) Details Cancer, Pediatric low-grade glioma | Approved Quarterly sales | |
Tovorafenib (DAY101) +/- Pimasertib Details Solid tumor/s, Cancer Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 1b Data readout | |
MTX-13 (DAY301) Details Solid tumor/s | Phase 1 Initiation |